| Title |
Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis
|
|---|---|
| Published in |
Molecular Diagnosis & Therapy, June 2018
|
| DOI | 10.1007/s40291-018-0344-x |
| Pubmed ID | |
| Authors |
Mingming Liang, Yun Zhang, Chenyu Sun, Feras Kamel Rizeq, Min Min, Tingting Shi, Yehuan Sun |
| Abstract |
The association between the checkpoint kinase 2*1100delC (CHEK2*1100delC) and breast cancer has been extensively explored. In light of the recent publication of studies on these specific findings, particularly regarding male patients with breast cancer, we performed an updated meta-analysis to investigate a more reliable estimate. This meta-analysis included 26 published studies selected in a search of electronic databases up to January 2018, including 118,735 breast cancer cases and 195,807 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association between 1100delC and breast cancer. Meta-analysis results suggested that 1100delC contributed to an increased breast cancer risk in overall populations (OR 2.89; 95% CI 2.63-3.16). Subgroup analysis found ORs of 3.13 (95% CI 1.94-5.07) for male breast cancer, 2.88 (95% CI 2.63-3.16) for female breast cancer, 2.87 (95% CI 1.85-4.47) for early-onset breast cancer, 2.92 (95% CI 2.65-3.22) for invasive breast cancer, and 3.21 (95% CI 2.41-4.29) for familial breast cancer. The sensitivity analysis suggested that results of this meta-analysis were generally robust. CHEK2*1100delC is associated with an increased risk of both female and male breast cancer. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| United Kingdom | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Scientists | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 22% |
| Other | 3 | 8% |
| Student > Master | 3 | 8% |
| Student > Doctoral Student | 3 | 8% |
| Librarian | 2 | 6% |
| Other | 8 | 22% |
| Unknown | 9 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 39% |
| Biochemistry, Genetics and Molecular Biology | 4 | 11% |
| Agricultural and Biological Sciences | 3 | 8% |
| Engineering | 2 | 6% |
| Immunology and Microbiology | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 9 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 June 2018.
All research outputs
#13,929,233
of 23,090,520 outputs
Outputs from Molecular Diagnosis & Therapy
#179
of 386 outputs
Outputs of similar age
#161,373
of 301,972 outputs
Outputs of similar age from Molecular Diagnosis & Therapy
#6
of 11 outputs
Altmetric has tracked 23,090,520 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 386 research outputs from this source. They receive a mean Attention Score of 3.6. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 301,972 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.